32 Biosciences pronounced "Three Squared Biosciences"Revolutionizing Healthcare: Harnessing Microbiome Science to Prevent and Treat Disease. 32 Biosciences is taking a new approach to medicine by using our field defining research to build clinically useful, validated, precision tools to diagnose and correct Dysbiosis (microbiome imbalance), a central but under-appreciated driver of human disease.In April of 2024, 32 Biosciences was formalized as the parent company to our two wholly-owned subsidiaries Gateway Biome and Covira.

Gateway Biome is a healthcare company, a spinout from The University of Chicago (Nov 2022). This microbiome-focused company is based on the work of world leading gut microbiome experts Eugene Chang, MD & Joseph Pierre, PhD. Gateway Biome's focus is to develop diagnostic/screening tools that leverage artificial intelligence to better understand the gut microbiome and prevent diseases. Gateway Biome's lead asset (GB-0001) measures the health of the gut microbiome in Adults ages 18-64.

Covira is a biotech company, a spinout from The University of Chicago (Sept 2018), developing drugs that work by modulating the biological activity of the gut microbiome to prevent diseases. This microbiome-focused company is based on the work of Dr. John Alverdy, MD, a world authority on the molecular basis of post-surgical infections. Covira’s platform technology generated a lead asset (CS-0003) that modulates bacterial virulence and restores microbial communities to prevent post-surgical infections. Covira’s approach is transformative to the field. In October 2022, after a 7-month competitive process with more than 4,000 early-stage US companies, Covira was named 1 of 16 Most Fundable Companies, Pepperdine Graziadio Business School Announces the 2022 List of Most Fundable Companies.- Built organization including Board of Directors, Chief Scientific Officer, Chief Regulatory Officer, Chief Financial Officer, Head of Finance & Accounting, General Counsel, Scientists, Scientific Advisory Board, Business Advisory Board and Key Business Partners.- Completed strategic plan for lead assets ($8.8B US TAM opportunity), to deliver US peak year sales of $2.5B.- Developed key partnerships with University of Chicago, Pritzker School of Molecular Engineering, Argonne National Laboratories, and IQVIA Biotech. Negotiated and closed research & development agreement with Fortune 100 company.

Medical Device Company. Responsible for building and leading VitaHEAT Medical and preparing the organization for the US launch of VitaHEAT UB3, a leading product technology designed to maintain normothermia throughout the peri-operative process in the $1.8B global surface warming market. - Hired and developed Senior Management Team; Sales, Marketing, Strategic Accounts, Commercial Operations, Customer Excellence, Human Resources, Finance/Accounting, Legal, Engineering, Quality & Regulatory Positions.- Executed Common Unit and Convertible Debt Offerings. Achieved capital raise targets from both new and existing investors/shareholders.- Completed Clinical Trials and launched VitaHEAT UB3 in April 2016. VitaHEAT UB3 is a leading product technology in the $1.8B global surface warming market. - Closed Series A Preferred Equity Investment with 3M Ventures (sponsored by 3Ms Infection Control Division), April 2017. - Achieved 40% YOY sales growth 2017 vs 2016 and captured over 1% market share of the addressable market.

In 2015 Abbott Laboratories revenues exceeded $20 billion (2019 revenues $31.9 billion) coming from four major business units Diagnostics, Medical Devices, Nutrition, and Established Pharmaceuticals.Positions Held (4)- Head of US Commercial Operations- Sr. Director Marketing, Sales & Business Development - Director Marketing & Sales- Director Marketing & Sales Operations

In 2006 Johnson & Johnson revenues exceeded $53 billion (2019 revenues $82.1 billion) coming from three major business units Pharmaceuticals, Medical Devices, and Consumer Products.*Start-up Pharmaceutical, Medical Device and Consumer Products Company. Successful exit, OraPharma, Inc. acquired by Johnson & Johnson in 2003 for $85MM.Positions Held (2) - Director US Strategic Accounts Business- Regional Sales Manager

*Start-up Pharmaceutical Company. Successful exit, Unimed Pharmaceuticals acquired by Solvay Pharmaceuticals for $123MM. Solvay acquired by Abbott Laboratories (now part of AbbVie, Inc.).Position Held- Product Manager

In 2001 Johnson & Johnson revenues exceeded $32 billion (2018 revenues $82 billion) coming from three major business units Pharmaceuticals, Medical Devices, and Consumer Products.Positions Held (4)- District Sales Manager- Neuroscience Specialty Sales Representative - Hospital Sales Representative - Primary Care Sales Representative

*Start-up Medical Device Company. Successful ongoing operations, Dynasplint Systems, Inc. remains a privately held company today.Position Held- Sales Representative